CTIG

Serial Number 85254479
604

Registration Progress

Application Filed
Mar 1, 2011
Under Examination
Approved for Publication
Jul 19, 2011
Published for Opposition
Jul 19, 2011
Registered

Trademark Image

CTIG

Basic Information

Serial Number
85254479
Filing Date
March 1, 2011
Published for Opposition
July 19, 2011
Abandonment Date
July 16, 2012
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
604
Status Date
Jul 16, 2012

Rights Holder

Cancer Therapeutics Innovation Group, LLC

16
Address
Apt. 223
303 Third Street
Cambridge, MA 02142

Ownership History

Cancer Therapeutics Innovation Group, LLC

Original Applicant
16
Cambridge, MA

Cancer Therapeutics Innovation Group, LLC

Owner at Publication
16
Cambridge, MA

Legal Representation

Attorney
Julia Huston, Esq.

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

15 events
Date Code Type Description Documents
May 21, 2014 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
May 21, 2014 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jul 16, 2012 OP.S T OPPOSITION SUSTAINED NO. 999999 Loading...
Jul 16, 2012 OP.T T OPPOSITION TERMINATED NO. 999999 Loading...
Jul 16, 2012 ABN4 O ABANDONMENT - AFTER INTER PARTES DECISION Loading...
Jul 16, 2012 MAB4 O ABANDONMENT NOTICE MAILED - INTER PARTES DECISION Loading...
Jan 13, 2012 OP.I T OPPOSITION INSTITUTED NO. 999999 Loading...
Aug 17, 2011 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED Loading...
Jul 19, 2011 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 19, 2011 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 2, 2011 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 1, 2011 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 5, 2011 MPMK O NOTICE OF PSEUDO MARK MAILED Loading...
Mar 4, 2011 NWAP I NEW APPLICATION ENTERED Loading...
Mar 4, 2011 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...

Additional Information

Pseudo Mark
CANCER THERAPEUTICS INNOVATION GROUP